Axogen, INC Form 4 insider transactions

Marc A Began, EVP & General Counsel of Axogen, Inc., sold 67,500 shares of common stock on August 10, 2026 for $47.34 per share.

Amy Mcbride Wendell, a Director of Axogen, Inc., sold 13,353 shares of common stock on August 11, 2026 for $48.42 per share.

Kathy Johnson Weiler, a Director of Axogen, Inc., sold 14,150 shares of common stock on August 7, 2026 for $45.30 per share.

Axogen, Inc. reports that Director William P. Burke received an annual equity grant of restricted stock units valued at $185,000.

Axogen, Inc. Director John Johnson was granted 4,392 restricted stock units as an annual equity award for his service.

Axogen, Inc. reports an annual equity grant to Director Alan M. Levine, valued at $185,000, vesting in one year.

Axogen, Inc. Director Thomas Paul was granted 5,579 restricted stock units valued at $235,000 as an annual equity award.

Axogen, Inc. Director Joseph A. Tyndall was granted 4,392 restricted stock units as an annual equity award for his service.

Axogen, Inc. Director Kathy Weiler received an annual equity grant of restricted stock units valued at $185,000.

Axogen, Inc. reports that Director Amy McBride-Wendell received an annual equity grant of restricted stock units valued at $185,000.

Axogen, Inc. Director Amy McBride-Wendell reported transactions involving the acquisition of common stock through option exercises and subsequent sale of shares.

Axogen, Inc. Director Kathy Weiler exercised 16,344 stock options and subsequently sold the shares on May 7, 2026.

Axogen, Inc. Chief Marketing Officer Jens Kemp sold 4,000 shares of common stock at an average price of $43.44.

Axogen, Inc. Sales VP Doris Quackenbush sold 3,878 shares of common stock on May 7, 2026.

Axogen's Chief Innovation Officer, Erick DeVinney, reported the vesting of restricted stock units and subsequent share dispositions for tax obligations on March 16, 2026.

Axogen CFO Lindsey Hartley reported the vesting of 9,000 restricted stock units and subsequent tax-related share withholdings.

Axogen's Chief Marketing Officer, Jens Kemp, reported the vesting of performance-based stock units and the grant of new restricted stock units, alongside tax-related share withholdings.

Axogen's Chief Innovation Officer, Erick DeVinney, reported the vesting of performance-based shares and restricted stock units, alongside tax-related share withholdings.

Axogen, Inc.'s EVP & General Counsel, Marc Began, reported the vesting of performance stock units and restricted stock units, alongside the acquisition of new restricted stock units.

Axogen CFO Lindsey Hartley reports vesting of performance-based shares and new restricted stock unit grant.

Axogen, Inc. CEO Michael D. Dale was granted 98,000 restricted stock units, vesting over four years.

Axogen CFO Lindsey Marie Hartley reported the vesting of 17,500 restricted stock units and the subsequent withholding of 6,704 shares for tax obligations.

Axogen Director Amy McBride Wendell exercised stock options and subsequently sold a portion of the acquired common stock on December 16, 2025, under a Rule 10b5-1 plan.

Axogen Director Kathy Johnson Weiler exercised stock options and sold a total of 46,653 shares of common stock on December 16, 2025.

Axogen's CFO, Lindsey Marie Hartley, executed a pre-planned transaction, exercising stock options and subsequently selling 14,812 shares of common stock.

Axogen, Inc. CEO Michael D. Dale reported a pre-planned sale of 25,000 shares of common stock at $30 per share, scheduled for December 10, 2025, reducing his direct beneficial ownership to 63,537 shares.

Axogen's EVP & General Counsel, Marc A. Began, reported the sale of 13,222 shares of common stock at $30 per share under a pre-arranged 10b5-1 plan.

Axogen CEO Michael D. Dale sold 61,463 shares of common stock for $31.208 per share to cover tax withholding obligations related to performance stock unit vesting.

Axogen Director Joseph A. Tyndall exercised stock options and subsequently sold the acquired common stock for a significant gain.

Axogen's Chief Innovation Officer, Erick DeVinney, sold 19,517 shares of common stock at $31.208 per share to cover tax withholding obligations related to vested performance stock units.